Brazil Breakthrough Cholesterol Pill Offers Statin Alternative for Millions
The U.S. Food and Drug Administration has granted priority review to Lipfendra1 (enlicitide), the first oral medication that blocks a protein called PCSK9. This protein plays a central role in how the body regulates bad cholesterol. Until now, drugs targeting PCSK9 were only available as injections given every few weeks.
PCSK9 is a protein made by the liver that reduces the body’s ability to clear LDL cholesterol from the blood. When the PCSK9 protein is blocked, the liver can pull more LDL out of circulation, and blood levels drop. Injectable PCSK9 inhibitors have been available for years and are highly effective. However, cost, access, and the need for self-injection have limited how widely they are used. An oral version removes some of those barriers.
High LDL cholesterol is one of the most common and modifiable risk factors for heart disease, the leading cause of death in the United States. Too much LDL in the blood can build up inside artery walls, forming plaques that narrow the arteries and restrict blood flow. If a plaque ruptures, it can trigger a clot, potentially leading to a heart attack or stroke. Guidelines from the American College of Cardiology and the American Heart Association set an LDL goal below 55 mg/dL for people at very high risk of a cardiovascular event.
The FDA approval follows two large, randomized, placebo-controlled trials involving 3,207 adults with severe high cholesterol. All participants were already taking the maximum tolerated dose of statin therapy. The first trial enrolled adults who either already had cardiovascular disease or were at high risk for it. Their average LDL at the start was 96 mg/dL. After 24 weeks, those taking Lipfendra saw an average LDL reduction of 56 percent compared to placebo.
The second trial focused on adults with heterozygous familial hypercholesterolemia (HeFH), an inherited condition that causes high LDL cholesterol. Their average starting LDL was 119 mg/dL. After 24 weeks, the Lipfendra group saw an average reduction of 59 percent compared to placebo. Clinical guidance says it is reasonable for adults already on the maximum statin dose but still above 70 mg/dL to consider adding a PCSK9 inhibitor. In the past, these people had to rely on injections. A pill that drops LDL by 56 to 59 percent can move many people closer to their cholesterol targets.
This new drug is not a replacement for statins. It is an add-on for people who still cannot reach their LDL targets with statins alone. It is approved for adults with high cholesterol or HeFH who are already on diet, exercise, and maximally tolerated statin therapy. People interested in Lipfendra should be aware of side effects. In the HeFH trial, people taking Lipfendra reported diarrhea and dizziness more often than the placebo group. No specific distinct side effects emerged in the cardiovascular disease trial, but the proportion of people who stopped treatment due to adverse reactions was similar in both trials.
While drug developments like this are promising, medication is one piece of a larger picture. According to the latest ACC/AHA guidelines on preventing cardiovascular disease, the most important foundation for preventing cardiovascular disease is a healthy lifestyle, and that comes before pharmacological therapy. The guideline recommends a diet rich in vegetables, fruits, whole grains, and lean protein, along with at least 150 minutes of moderate-intensity physical activity per week.
For many people, those changes are enough to move LDL in the right direction. When they are not enough on their own, statins are typically the next step. When statins, even at the maximum dose, still leave LDL above target, add-on therapies like Lipfendra come in. This is the treatment ladder for high cholesterol, and Lipfendra sits at the top for people who have worked their way up the other rungs.
A once-daily pill that can cut LDL by more than half is a significant development. It will hopefully open the door to better cholesterol control for people who previously had limited options. If you or someone you know has been managing high cholesterol with a healthy lifestyle and statins without reaching target LDL levels, it may be worth a conversation about this approval with a doctor.
